The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis
Open accessAbstract
BACKGROUND: The risk of second primary malignancies (SPMs) associated with cancer therapies is an important concern of thyroid cancer survivors and physicians. Our objective was to determine if the risk of SPMs is increased in individuals with thyroid cancer treated with radioactive iodine (RAI), compared to those not treated with RAI. METHODS: We performed a systematic review of the literature and meta-analysis. Two independent reviewers screened citations and reviewed full-text papers. If not reported by the primary authors, the relative risk (RR) of SPMs was calculated by dividing the standardized incidence ratio of SPM in individuals with thyroid cancer treated with RAI compared to those not treated with RAI (with associated 95% confidence intervals [CI]). The natural logarithms of RRs of respective SPMs, weighted by the inverse of the variance, were pooled using fixed effects models and the exponential of the results was reported. RESULTS: Two multi-center studies (one from Europe and the other from North America) were included in this review. The RR of SPMs in thyroid cancer survivors treated with RAI was significantly increased at 1.19 (95% confidence interval [CI] 1.04, 1.36, p = 0.010), relative to thyroid cancer survivors not treated with RAI (data from 16,502 individuals), using a minimum latency period of 2 to 3 years after thyroid cancer diagnosis. The RR of leukemia was also significantly increased in thyroid cancer survivors treated with RAI, with an RR of 2.5 (95% CI 1.13, 5.53, p = 0.024). We did not observe a significantly increased risk of the following cancers related to prior RAI treatment: bladder, breast, central nervous system, colon and rectum, digestive tract, stomach, pancreas, kidney (and renal pelvis), lung, or melanoma of skin. CONCLUSIONS: The risk of SPMs in thyroid cancer survivors treated with RAI is slightly increased compared to thyroid cancer survivors not treated with RAI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citation(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,016
Pacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,976
Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data
Verdecchia, A., Francisci, S., Brenner, H., Gatta, G., Micheli, A., Mangone, L., & Kunkler, I. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70246-2 · Cited by 1,285
Hayat, M. J., Howlader, N., Reichman, M. E., & Edwards, B. K. (2007) · The Oncologist · doi:10.1634/theoncologist.12-1-20 · Cited by 1,096
Edwards, B. K., Howe, H. L., Ries, L. A. G., Thun, M. J., Rosenberg, H. M., Yancik, R., Wingo, P. A., Jemal, A., & Feigal, E. G. (2002) · Cancer · doi:10.1002/cncr.10593 · Cited by 880
Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy
Jonklaas, J., Sarlis, N. J., Litofsky, D., Ain, K. B., Bigos, S. T., Brierley, J. D., Cooper, D. S., Haugen, B. R., Ladenson, P. W., Magner, J., et al. (2006) · Thyroid · doi:10.1089/thy.2006.16.1229 · Cited by 695
Self-citationSecond primary malignancies in thyroid cancer patients
Rubino, C., de Vathaire, F., Dottorini, M. E., Hall, P., Schvartz, C., Couette, J. E., Dondon, M. G., Abbas, M. T., Langlois, C., & Schlumberger, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601319 · Cited by 655
Cited by
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Current Thyroid Cancer Trends in the United States
Davies, L., & Welch, H. G. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1 · Cited by 1,615
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Cabanillas, M. E., McFadden, D. G., & Durante, C. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30172-6 · Cited by 1,430
Metadata
- Authors
- Sawka, A. M., Thabane, L., Parlea, L., Ibrahim-Zada, I., Tsang, R. W., Brierley, J. D., Straus, S., Ezzat, S., & Goldstein, D. P.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2009-05
- Volume
- 19
- Issue
- 5
- Pages
- 451-457
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W2033297297
- Cited by
- 350
- References
- 25
- FWCI
- 12.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.1089/thy.2008.0392
- The paper
- Sawka, A. M., Thabane, L., Parlea, L., Ibrahim-Zada, I., Tsang, R. W., Brierley, J. D., Straus, S., Ezzat, S., & Goldstein, D. P. (2009). Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis. Thyroid. https://doi.org/10.1089/thy.2008.0392
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.